Ezra Cohen, MD
Immunotherapy and novel multikinase inhibitors continue to play an important role for patients with head and neck cancer, particularly as ongoing clinical trials are further exploring these agents.
on Head and Neck Squamous Cell Carcinoma and Thyroid Cancer, Cohen, professor of medicine, Division of Hematology/Oncology, associate director for Translational Science, Moores Cancer Center, University of California (UC), San Diego, discussed the role of immunotherapy, the potential of entrectinib, and the importance of multidisciplinary teams for the treatment of patients with head and neck cancer.
OncLive: Can you provide an overview of treatment options for patients with advanced head and neck cancer?
There are [immunotherapy] drugs and single agents for patients with platinum-refractory disease. In my talk, I discussed those data and the reason behind their approvals.
... to read the full story